Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug better prevents transplant complications in older leukemia patients?

NCT ID NCT06083129

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests two drugs, Thymoglobulin and Grafalon, to see which one better prevents graft-versus-host disease (GVHD) in patients aged 50-70 with acute myeloid leukemia or myelodysplastic syndrome. All participants receive a stem cell transplant from a matched unrelated donor. The study aims to reduce GVHD severity and improve recovery without increasing cancer relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Thymoglobulin and Grafalon (anti-thymocyte globulins)
What this could lead to
If successful, this study could identify the better drug to prevent graft-versus-host disease, improving survival and quality of life for older leukemia patients after transplant.
What could go wrong
This is a head-to-head comparison of two existing drugs, so no breakthrough cure is expected. Results may show only a modest benefit, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia graft versus host disease myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD

Contacts and locations

Locations

  • CHRU Nancy

    RECRUITING

    Nancy, France

  • CHRU Strasbourg

    RECRUITING

    Strasbourg, France

  • CHRU Tours

    NOT_YET_RECRUITING

    Tours, France

  • CHU Amiens

    RECRUITING

    Amiens, France

  • CHU Angers

    RECRUITING

    Angers, France

  • CHU Besançon

    RECRUITING

    Besançon, France

  • CHU Bordeaux

    RECRUITING

    Bordeaux, France

  • CHU Brest

    RECRUITING

    Brest, France

  • CHU Caen

    RECRUITING

    Caen, France

  • CHU Clermont-Ferrand

    RECRUITING

    Clermont-Ferrand, France

  • CHU Grenoble

    RECRUITING

    Grenoble, France

  • CHU Lille

    RECRUITING

    Lille, France

  • CHU Limoges

    RECRUITING

    Limoges, France

  • CHU Lyon Sud

    RECRUITING

    Lyon, France

  • CHU Montpellier

    RECRUITING

    Montpellier, France

  • CHU Nantes

    RECRUITING

    Nantes, France

  • CHU Nice

    RECRUITING

    Nice, France

  • CHU Poitiers

    RECRUITING

    Poitiers, France

  • CHU Rennes

    RECRUITING

    Rennes, France

  • CHU Saint Etienne

    RECRUITING

    Saint-Etienne, France

  • Hôpital Henri Mondor AP-HP

    NOT_YET_RECRUITING

    Créteil, France

  • Hôpital La Pitié Salpêtrière AP-HP

    RECRUITING

    Paris, France

  • Hôpital Necker AP-HP

    RECRUITING

    Paris, France

  • Hôpital Saint Louis AP-HP

    RECRUITING

    Paris, France

  • Hôpital Saint-Antoine AP-HP

    RECRUITING

    Paris, France

  • IPC Marseille

    RECRUITING

    Marseille, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

  • Oncopole Toulouse

    RECRUITING

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.